Nidan Laboratories & Healthcare Ltd
Incorporated in 2000, Nidan Laboratories & Healthcare Ltd is in the business of providing various Healthcare and Diagnostics Services[1]
- Market Cap ₹ 18.6 Cr.
- Current Price ₹ 13.4
- High / Low ₹ 24.9 / 11.5
- Stock P/E 10.6
- Book Value ₹ 50.1
- Dividend Yield 0.00 %
- ROCE 5.99 %
- ROE 2.55 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.27 times its book value
- Company's working capital requirements have reduced from 87.8 days to 33.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 4.62% over past five years.
- Company has a low return on equity of 1.81% over last 3 years.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 20.07 | 21.41 | 20.38 | 29.66 | 24.27 | 24.18 | 24.53 | 25.54 | |
| 12.23 | 13.78 | 11.49 | 20.25 | 17.47 | 17.74 | 19.47 | 20.70 | |
| Operating Profit | 7.84 | 7.63 | 8.89 | 9.41 | 6.80 | 6.44 | 5.06 | 4.84 |
| OPM % | 39.06% | 35.64% | 43.62% | 31.73% | 28.02% | 26.63% | 20.63% | 18.95% |
| 0.37 | 0.01 | 1.06 | 0.40 | 3.33 | -3.76 | 2.25 | 1.46 | |
| Interest | 4.75 | 3.74 | 3.46 | 2.66 | 2.22 | 2.18 | 2.14 | 1.96 |
| Depreciation | 3.24 | 3.19 | 3.18 | 2.63 | 3.10 | 2.87 | 2.41 | 1.90 |
| Profit before tax | 0.22 | 0.71 | 3.31 | 4.52 | 4.81 | -2.37 | 2.76 | 2.44 |
| Tax % | 0.00% | 0.00% | 30.21% | 41.15% | 26.40% | 36.29% | 28.26% | 38.11% |
| 0.22 | 0.71 | 2.30 | 2.66 | 3.54 | -3.23 | 1.98 | 1.51 | |
| EPS in Rs | 0.22 | 0.72 | 2.32 | 1.91 | 2.55 | -2.32 | 1.42 | 1.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -19% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -27% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.90 | 9.90 | 9.90 | 13.90 | 13.90 | 13.90 | 13.90 | 13.90 |
| Reserves | 0.41 | 1.13 | 3.43 | 52.00 | 55.54 | 52.31 | 54.28 | 55.79 |
| 32.16 | 34.35 | 38.04 | 19.29 | 10.93 | 12.44 | 11.11 | 11.17 | |
| 0.58 | -0.17 | 2.37 | 3.29 | 4.03 | 3.90 | 3.65 | 3.14 | |
| Total Liabilities | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 84.00 |
| 23.28 | 20.10 | 19.92 | 20.46 | 21.39 | 17.95 | 16.33 | 14.91 | |
| CWIP | 0.00 | 0.00 | 0.23 | 3.81 | 0.00 | 0.04 | 0.15 | 0.15 |
| Investments | 0.53 | 0.53 | 0.27 | 0.00 | 0.00 | 0.00 | 20.00 | 20.00 |
| 19.24 | 24.58 | 33.32 | 64.21 | 63.01 | 64.56 | 46.46 | 48.94 | |
| Total Assets | 43.05 | 45.21 | 53.74 | 88.48 | 84.40 | 82.55 | 82.94 | 84.00 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 8.95 | 4.62 | 4.35 | 7.83 | 10.97 | 5.52 | 2.28 | 1.67 | |
| 1.00 | -0.01 | -3.22 | -35.74 | -0.29 | -10.60 | -0.22 | 0.06 | |
| -5.81 | -1.56 | -1.22 | 28.72 | -10.37 | -0.49 | -3.01 | -1.63 | |
| Net Cash Flow | 4.14 | 3.05 | -0.10 | 0.80 | 0.32 | -5.57 | -0.95 | 0.10 |
| Free Cash Flow | 9.95 | 4.61 | 1.13 | 1.36 | 11.02 | 4.88 | 1.41 | 1.19 |
| CFO/OP | 114% | 61% | 49% | 96% | 162% | 129% | 77% | 55% |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102.03 | 92.57 | 97.25 | 65.96 | 90.69 | 7.85 | 18.90 | 31.73 |
| Inventory Days | 16.98 | 12.88 | 18.17 | 25.99 | ||||
| Days Payable | 116.72 | -25.76 | 213.05 | 135.84 | ||||
| Cash Conversion Cycle | 2.29 | 131.22 | -97.64 | -43.89 | 90.69 | 7.85 | 18.90 | 31.73 |
| Working Capital Days | 256.25 | 291.69 | -189.31 | 54.52 | 43.46 | 243.18 | -13.39 | 33.58 |
| ROCE % | 10.13% | 13.99% | 10.09% | 8.17% | 7.95% | 6.17% | 5.99% |
Insights
In beta| Mar 2015 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Permanent Employees count |
|
||||
| Pathology Revenue Share % |
|||||
| Radiology Revenue Share % |
|||||
| Number of Diagnostic Centres count |
|||||
| Number of Diagnostic Services Offered count |
|||||
Extracted by Screener AI
Documents
Announcements
-
Copy of Newspaper Publication
- 26th AGM on 28 September 2026; book closure 22-28 September, remote e-voting enabled.
-
Shareholders meeting
- FY2025-26 annual report issued; 26th AGM on 28 September 2026 via VC/OAVM.
-
Updates
- Board approved 26th AGM on 28 September 2026; book closure 22–28 September, remote e-voting enabled.
-
Outcome of Board Meeting
- Board approved 26th AGM on 28 September 2026, with book closure from 22-28 September and remote e-voting.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Filed Regulation 74(5) certificate for quarter ended 30 June 2026.
Annual reports
-
Annual Report 2026
from nse
-
Annual Report 2025
from nse
-
Annual Report 2024
from nse
-
Annual Report 2023
from nse
-
Annual Report 2022
from nse
Business Overview:[1]
NLHL is a Healthcare Division of Nidan Group. It operates 35 diagnostic centers across Greater Mumbai under the Nidan Diagnostics brand. Services include CT scan, MRI, Ultrasound, 2D Echo, ECG, and more.